Accustem Sciences Inc.

AccuStem Sciences, Inc. is a clinical-stage diagnostics company that develops and commercializes genomic tests to assist decision-making across oncology care. Its proprietary test pipeline includes the MicroRNA Signature Classifier, a 24-microRNA blood-based assay designed to determine whether lung nodules identified through low-dose computed tomography screening are benign or malignant. The company also develops StemPrintER, a 20-gene prognostic assay measuring tumor stemness to evaluate the risk of distant recurrence in patients diagnosed with early-stage, luminal breast cancer. Additionally, it plans to provide ancillary testing services such as hereditary genetic and somatic mutation panels.

The business targets its initial commercialization activities within the United States. To support test processing, transfer, and reporting under clinical laboratory standards, the company collaborates with a partner commercial laboratory based in Lake Forest, California. AccuStem Sciences maintains its principal executive offices in New York, New York.

Summary of the business section of Accustem Sciences's latest annual report, written by StockData.

“As of December 31, 2025, we had four full time employees.”